ClinicalTrials.gg
CompletedNCT01771809TURANDOT IIUpdated Jun 3, 2021Results posted

Long-Term Safety Of PF-00547659 In Ulcerative Colitis

A Phase 2 interventional study of 75mg SHP647 (PF-00547659) and 225mg SHP647 (PF-00547659) in Ulcerative Colitis, sponsored by Shire. Completed at 99 sites in 21 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Colitis, Ulcerative by Takeda — 6 open to participants now, 10 under way, 5 of them phase 3. Colitis, Ulcerative · Takeda.

Enrollment
16th of 43
330 · median 240
Started
2013
the only one that year
Phase 2
10 of 68
1 open now
Registered
15th of 68
by date

Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 16th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2013, is one of 10 in phase 2, and was the 15th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 68 studies in Colitis, Ulcerative by Takeda are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Colitis, Ulcerative by Takeda, or all of them as a file.
02

Study summary

Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Anti-TNF Refractory
  • Active Ulcerative Colitis
  • Immunosuppressant Refractory
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects between 18 and 66 years of age.
  • Subjects previously enrolled in study A7281009 (NCT01620255) who have completed the 84 day (12 week) induction period.

Exclusion criteria

Exclusion Criteria:

  • Subjects that have completed Day 84 (Week 12) of study A7281009 but have experienced serious event(s) related to the product, an unstable medical condition, or any other reason, in the opinion of the investigator, would preclude entry or participation in this study.
  • Subjects who are taking any dose of Azathioprine (AZA), 6-mercaptopurine(6 MP) or Methotrexate (MTX).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    SHP647 75 mg

    Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.

    Drug: 75mg SHP647 (PF-00547659)

  • Experimental
    SHP647 225 mg

    Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.

    Drug: 225mg SHP647 (PF-00547659)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who was administered a product or medical device; the event did not need to necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect. Number of participants with TEAEs, STEAEs, and those withdrew from treatment due to TEAEs were reported.

    Time frame: From start of study drug administration up to 168 weeks

Secondary outcomes

  1. Percentage of Participants With Mucosal Healing at Week 16

    Mucosal healing was defined as an absolute Mayo subscore for endoscopy of 0 or 1 (based on centrally read score) as assessed by flexible sigmoidoscopy or colonoscopy. The Mayo score is a tool designed to measure disease activity for ulcerative colitis (UC). The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy, and physician's global assessment \[PGA\]) each graded 0 to 3 with the higher score indicating more severe disease activity. The percentage of participants with mucosal healing at week 16 was reported.

    Time frame: Week 16

  2. Serum Trough Concentrations of SHP647 Versus Time

    Serum trough concentrations of SHP647 versus time was reported.

    Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72 and 156

  3. Number of Participants With Positive Anti-drug (SHP647) Antibodies (ADA)

    The anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64. The number of participants with positive ADA was reported.

    Time frame: Baseline, Week 8, 16, 24, 40, 48, 64 and 156

  4. Number of Participants With Positive Neutralizing Antibodies (NAb)

    The positive Neutralizing Antibodies (NAb) was defined as NAb titer greater than or equal to (\>=) 0.903. The number of participants with NAb was reported. Here "inconclusive" refers to participants who were neither reported as positive nor negative for NAb and anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64.

    Time frame: Baseline, Week 8, 16, 24, 40, 48, 64 and 156

07

Results

Posted Apr 18, 2019

Participant flow

The study was conducted at 101 centers in 21 countries between 18 Mar 2013 (first participant first visit) and 13 Dec 2017 (last participant last visit).

Participant flow — Overall Study
MilestoneSHP647 75 mgSHP647 225 mg
Started164166
Completed9383
Not completed7183
Withdrew: Adverse event412
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject3442
Withdrew: Lost to follow-up13
Withdrew: Other (insufficient clinical response)2220
Withdrew: Death10
Withdrew: Other (other)95

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who was administered a product or medical device; the event did not need to necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect. Number of participants with TEAEs, STEAEs, and those withdrew from treatment due to TEAEs were reported.

Time frame:
From start of study drug administration up to 168 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs)
ParticipantsSHP647 75 mgSHP647 225 mg
Participants with any TEAE146147
Participants with any TESAE3440
Participants who withdrew treatment due to TEAE1223
SecondaryPercentage of Participants With Mucosal Healing at Week 16

Mucosal healing was defined as an absolute Mayo subscore for endoscopy of 0 or 1 (based on centrally read score) as assessed by flexible sigmoidoscopy or colonoscopy. The Mayo score is a tool designed to measure disease activity for ulcerative colitis (UC). The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy, and physician's global assessment \[PGA\]) each graded 0 to 3 with the higher score indicating more severe disease activity. The percentage of participants with mucosal healing at week 16 was reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing at Week 16
Percentage of participantsSHP647 75 mgSHP647 225 mg
Percentage of Participants With Mucosal Healing at Week 1627.429.5
SecondarySerum Trough Concentrations of SHP647 Versus Time

Serum trough concentrations of SHP647 versus time was reported.

Time frame:
Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72 and 156
Reported as:
Mean · Micrograms/liter (ug/L)
Serum Trough Concentrations of SHP647 Versus Time
Micrograms/liter (ug/L)SHP647 75 mgSHP647 225 mg
Baseline6398.62 ± 8584.4128064.41 ± 10629.768
Week 45496.56 ± 4026.75916787.31 ± 7807.292
Week 86245.79 ± 3371.70820345.29 ± 9286.956
Week 129038.72 ± 5540.83623915.87 ± 10434.073
Week 1610445.24 ± 6387.00424772.35 ± 11970.153
Week 2010928.76 ± 7900.85925582.98 ± 11767.775
Week 2411145.54 ± 8019.86427832.20 ± 12469.086
Week 2812978.11 ± 8772.28527797.77 ± 13070.361
Week 3212926.04 ± 8798.67128381.93 ± 11748.573
Week 3612785.55 ± 9182.50129666.64 ± 13997.231
Week 4013004.90 ± 9544.67528947.34 ± 12151.971
Week 4413337.50 ± 8620.54929855.69 ± 13605.897
Week 4814061.44 ± 9257.99130010.61 ± 14014.183
Week 5214192.83 ± 9326.17628917.76 ± 14545.617
Week 5615179.77 ± 10405.99629985.88 ± 14122.172
Week 6015133.54 ± 9673.60229086.78 ± 12606.888
Week 6415354.29 ± 10112.09831613.08 ± 13712.478
Week 6815584.38 ± 10407.78130609.08 ± 14331.857
Week 7215006.48 ± 9390.02031342.89 ± 14012.311
Week 156983.49 ± 1485.7081893.88 ± 4530.680
SecondaryNumber of Participants With Positive Anti-drug (SHP647) Antibodies (ADA)

The anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64. The number of participants with positive ADA was reported.

Time frame:
Baseline, Week 8, 16, 24, 40, 48, 64 and 156
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug (SHP647) Antibodies (ADA)
ParticipantsSHP647 75 mgSHP647 225 mg
Baseline910
Week 831
Week 1611
Week 2411
Week 4012
Week 4810
Week 6410
Week 15601
SecondaryNumber of Participants With Positive Neutralizing Antibodies (NAb)

The positive Neutralizing Antibodies (NAb) was defined as NAb titer greater than or equal to (\>=) 0.903. The number of participants with NAb was reported. Here "inconclusive" refers to participants who were neither reported as positive nor negative for NAb and anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64.

Time frame:
Baseline, Week 8, 16, 24, 40, 48, 64 and 156
Reported as:
Count of participants · Participants
Number of Participants With Positive Neutralizing Antibodies (NAb)
ParticipantsSHP647 75 mgSHP647 225 mg
Baseline: Without +ADA139143
Baseline: With +ADA, with +NAb04
Baseline: With +ADA, without +NAb01
Baseline: With +ADA, with inconclusive NAb85
Baseline: With +ADA, missing NAb10
Week 8: Without +ADA140150
Week 8: With +ADA, with +NAb11
Week 8: With +ADA, without +NAb20
Week 16: Without +ADA139143
Week 16: With +ADA, with +NAb01
Week 16: With +ADA, without +NAb10
Week 24: Without +ADA105118
Week 24: With +ADA, with +NAb01
Week 24: With +ADA, without +NAb10
Week 40: Without +ADA93102
Week 40: With +ADA, with +NAb12
Week 40: With +ADA, without +NAb00
Week 48: Without +ADA9692
Week 48: With +ADA, with +NAb10
Week 48: With +ADA, without +NAb00
Week 64: Without +ADA8286
Week 64: With +ADA, with +NAb00
Week 64: With +ADA, without +NAb10
Week 156: Without +ADA7380
Week 156: With +ADA, with +NAb00
Week 156: With +ADA, without +NAb01

Adverse events

Collected over From start of study drug administration up to 168 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHP647 75 mg1/164 (0.6%)34/164 (20.7%)116/164 (70.7%)
SHP647 225 mg0/166 (0%)40/166 (24.1%)119/166 (71.7%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventSHP647 75 mgSHP647 225 mg
Colitis ulcerativeGastrointestinal disorders15/16418/166
AnaemiaBlood and lymphatic system disorders2/1641/166
GastroenteritisInfections and infestations2/1641/166
DehydrationMetabolism and nutrition disorders0/1642/166
HeadacheNervous system disorders0/1642/166
Serous cystadenocarcinoma ovaryNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1640/166
Retinal detachmentEye disorders1/1640/166
DiarrhoeaGastrointestinal disorders1/1640/166
Duodenal ulcerGastrointestinal disorders1/1640/166
EnteritisGastrointestinal disorders1/1640/166
Most frequent other events
Showing 10 of 21
Most frequent other events
EventSHP647 75 mgSHP647 225 mg
Colitis ulcerativeGastrointestinal disorders41/16436/166
ArthralgiaMusculoskeletal and connective tissue disorders27/16429/166
NasopharyngitisInfections and infestations20/16428/166
Upper respiratory tract infectionInfections and infestations23/16420/166
HeadacheNervous system disorders17/16421/166
CoughRespiratory, thoracic and mediastinal disorders20/16411/166
Abdominal painGastrointestinal disorders9/16420/166
NauseaGastrointestinal disorders8/16419/166
GastroenteritisInfections and infestations18/16413/166
Back painMusculoskeletal and connective tissue disorders12/16418/166

Baseline characteristics

Safety analysis set (SAS) consisted of all enrolled participants who had received at least 1 dose of SHP647.

Age, Continuous
Age, Continuous(Years)SHP647 75 mgSHP647 225 mgTotal
Mean40.5 ± 12.7541.1 ± 13.6840.8 ± 13.21
Sex: Female, Male
Sex: Female, Male(Participants)SHP647 75 mgSHP647 225 mgTotal
Female6270132
Male10296198
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SHP647 75 mgSHP647 225 mgTotal
Hispanic or Latino4610
Not Hispanic or Latino160160320
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SHP647 75 mgSHP647 225 mgTotal
Race — American Indian or Alaska Native000
Race — Asian111526
Race — Native Hawaiian or Other Pacific Islander000
Race — Black or African American325
Race — White148143291
Race — More than one race000
Race — Other268
08

Study locations

99 sites
  • Mayo Clinic Arizona - Scottsdale
    Scottsdale, Arizona 85259, United States
  • UCSD Altman Clinical and Translational Research Institute
    La Jolla, California 92093, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • Rocky Mountain Gastroenterology
    Thornton, Colorado 80229, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Bassan and Bloom M.D.s
    Miramar, Florida 33025, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Commonwealth Clinical Studies
    Brockton, Massachusetts 02302, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Minnesota Gastroenterology, PA
    Plymouth, Minnesota 55446, United States
  • Center for Digestive and Liver Diseases
    Mexico, Missouri 65265, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nevada School of Medicine
    Las Vegas, Nevada 89102, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Weill Cornell Medical College of Cornell University
    New York, New York 10021, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • UNC Memorial Hospital
    Chapel Hill, North Carolina 27599, United States
  • The Oregon Clinic-West Hills Gastroenterology Associates, P.C.
    Portland, Oregon 97225, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Baylor College Of Medicine - Baylor Medical Center
    Houston, Texas 77030, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Univeristy of Washington
    Seattle, Washington 98195, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Mater Health Services
    South Brisbane, Queensland 4101, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
  • AKH Wien, Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • AZ St. Elisabeth Herentals
    Herentals, 2200, Belgium
  • University Hospital Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier de Mouscron
    Mouscron, 7700, Belgium
  • MBAL Sveti Ivan Rilski, Klinika po Gastroenterologia
    Sofia, 1431, Bulgaria
  • (G.I.R.I.) GI Research Institute
    Vancouver, British Columbia V6Z 2K5, Canada
  • Percuro Clinical Research, Ltd
    Victoria, British Columbia V8V 3P9, Canada
  • Hamilton Health Sciences Corp, McMaster Univ Medical Centre
    Hamilton, Ontario L8S 4K1, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Taunton Surgical Centre
    Oshawa, Ontario L1H 7K4, Canada
  • Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
    Montreal, Quebec H1T 2M4, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Hepato-Gastroenterologie HK s.r.o. Poliklinika III
    Hradec Kralove, 50012, Czechia
  • IBD Clinical and Research Centre
    Prague, 170 04, Czechia
  • Krajska zdravotni, a.s., Masarykova nemocnice v Usti nad Labem
    Usti nad Labem, 401 13, Czechia
  • CHU Amiens-Picardie - Hopital Sud
    Amiens, 80054, France
  • Centre Hospitalier Universitaire (CHU) de Caen - Hopital Cote de Nacre
    Caen, 14033, France
  • Hopital Huriez CHRU de Lille
    Lille, 59037 Cedex, France
  • CHU De Nice Hopital De L'Archet II
    Nice Cedex 03, 06200, France
  • CHU de Saint-Etienne Hopital Nord
    Saint Priest En Jarez, 42270, France
  • CHU de Nancy - Hopital Brabois
    Vandoeuvre les Nancy, 54511, France
  • Universitaetsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein 24105, Germany
  • Universitaetsklinikum Regensburg, Klinik und Poliklinik fuer Innere Medizin 1
    Regensburg, 93053, Germany
  • Csongrad Megyei Dr. Bugyi Istvan Korhaz
    Szentes, Csongrad 6600, Hungary
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Hadassah Ein Kerem University Hospital - Gastroenterology and Liver Diseases Unit
    Jerusalem, 91120, Israel
  • Meir Medical Center
    Kfar-Saba, 44281, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, 5262000, Israel
  • Universita' degli Studi "Magna Graecia" di Catanzaro
    Catanzaro, 88100, Italy
  • Milan University, Humanitas Clinical Institute
    Milano, 20089, Italy
  • Policlinico Universitario Campus Bio-Medico
    Roma, 00128, Italy
  • Azienda Ospedaliera Universitaria, Policlinico Tor Vergata
    Roma, 00133, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 00152, Italy
  • Universita Cattolica del Sacro Cuore
    Roma, 00168, Italy
  • Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • Yeungnam University Medical Center
    Daegu, 42415, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • University Medical Center Groningen (UMCG)
    Groningen, 9713 GZ, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Christchurch Hospital
    Christchurch, Canterbury 8140, New Zealand
  • Waikato Hospital
    Hamilton, 3240, New Zealand
  • Centrum Endoskopii Zabiegowej
    Bydgoszcz, Kujawsko-Pomorskie 85-168, Poland
  • Centrum Medyczne-Szpital Swietej Rodziny Sp.z.o.o.
    Lodz, Wojlodzkie 90-302, Poland
  • Gabinet Endoskopii Przewodu Pokarmowego
    Krakow, 31-009, Poland
  • NZOZ Centrum Medyczne HCP sp. z o.o
    Poznan, 61-485, Poland
  • Klinika Chorob Wewnetrznych I Gastroenterologii
    Warszawa, 02-507, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED
    Warszawa, 03-580, Poland
  • Lexmedica
    Wroclaw, 53-114, Poland
  • St. Petersburg State Medical Academy for Postgraduate Education
    Saint-Petersburg, 191015, Russian Federation
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Clinical Hospital Center Zemun
    Belgrade, 11080, Serbia
  • Clinical Hospital Centre Bezanijska Kosa
    Belgrade, 11080, Serbia
  • Ustredna vojenska nemocnica SNP Ruzomberok - Fakultna nemocnica
    Nitra, 949 01, Slovakia
  • Gastro L., s.r.o.
    Presov, 080 01, Slovakia
  • Ustredna vojenska nemocnice SNP Ruzomberok - Fakultna nemocnica
    Ruzomberok, 034 26, Slovakia
  • Kingsbury Hospital
    Claremont, Cape Town 7708, South Africa
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Centro Medico Teknon-Institut de la Macula i de la Retina
    Barcelona, 08022, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Parc de Salut Mar-Hospital del Mar
    Barcelona, 8003, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Dec 2017, 56 months.

Results were first posted in Apr 2019, 1 year 4 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 56 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2013
First posted
Jan 18, 2013
StartActual
Mar 18, 2013
Primary completionActual
Dec 13, 2017
CompletionActual
Dec 13, 2017
Results first posted
Apr 18, 2019
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01771809
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 18, 2013
Start date
Mar 18, 2013
Primary completion
Dec 13, 2017
Completion
Dec 13, 2017
Results posted
Apr 18, 2019
Last update
Jun 3, 2021

Study contacts

Shire Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion